Nomination Summary for Hydrochlorothiazide/UV light (solar simulated light) (N21307)
Nominated Substances: Hydrochlorothiazide
Nomination Date: 08/12/2013
Nominator: Private Individual
Rationale: Hydrochlorothiazide is a widely used diuretic used to treat hypertension, congestive heart failure, and other fluid retention disorders. Although human epidemiology studies have associated hydrochlorothiazide use with lip and cutaneous malignancies, the limited nature of the epidemiologic evidence and the small magnitude of the observed associations, only gave enough evidence for IARC to classify these findings as a 2B effect (possibly carcinogenic to humans). Furthermore, there were no data from animal cancer bioassays on the carcinogenic effects of hydrochlorothiazide/UV light combination exposure. Several members of the IARC Monographs Vol. 108 Working Group (J Dunnick, NIEHS; F. Beland, NCTR; Y. Grosse, IARC; W. Jameson, Toxicology Consultant) felt that the results of a hydrochlorothiazide/UV (solar simulated light) cancer study using the HRA mouse model would add to the understanding of hydrochlorothiazide carcinogenic potential.
NTP Principles: not specified